@Revolution:Global Business News

New Economy, Leadership, Entrepreneurship, Management, Global Business

Amgen’s Crisis Play

Posted by iBlog on August 20, 2007

The perils of pushing some drugs too hard and too broadly came home to roost Wednesday as Amgen announced a restructuring that includes laying off as many as 2,600 people and cutting spending by $1.9 billion. Amgen, long regarded as one of the kings of the biotech world, has been under intense scrutiny from the Food and Drug Administration and the Centers for Medicare and Medicaid Services in recent months regarding one of its top-selling drugs, Aranesp, used to treat anemia in patients undergoing chemotherapy.Read the full article in Forbes.com


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: